Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
They notify the regulator by 3:30pm the trading day following a change in their position.
On a side note, the FUD spammers seem to have partly dried up since the strong bounce from below 50. A few bandwagon-jumpers still going on who haven’t yet got the memo.
Is this our turning point? Would be nice to close the day green, after strong market rejection of that sub-50p SP.
Could be back to back, but more likely this:
https://www.investopedia.com/terms/b/btob.asp
Sounds like maybe subcontracting the platform to an external partner to run the consumer-facing part. MOS have got the great product. Maybe this is the mostt efficient way to roll it out into more territories, more quickly.
Interesting article. So humbling.
Try this one as well (although many other sources exist I’m sure). The list of side effects with % of occurrences on page 3 is pretty grim reading. I
https://www.cancercareontario.ca/en/system/files_force/doxorubicin.pdf?download=1
While cardiotoxicity and myelosuppression might be the two biggest ticket common side effects to reduce, It’ll be very interesting to see if there is an impact on the also common symptoms of nausea and hair loss. While both of these might not be life-threatening per se, it will be a significant quality of life improvement for the patients, and a very visible outward sign of an improved safety profile.
I do hope the LFT negative sentiment is fully priced in now, and that nobody is still in for that project.
Maybe it makes a comeback and produces some revenues. But at this stage I’d much rather this happens in a low-key manner that doesn’t attract volatile investors back in. We need sticky hands with deep pockets. Bad mixed metaphor, but you get the point!
For me it’s not all or nothing on AVA6000/PreCision now. It’s just the next shot on goal. There are still a lot of shots to take based on the Affimer platform, with just slightly longer timeframes. LG Chem look bound for the clinic with the PD-L1 inhibiting Affimers, following promising pre-clinical results and nice progress on this licensing deal. This uses a tool and a mechanism that is completely independent from PreCision, and over the longer term is another project that could be worth >$1bn plus royalties to Avacta. Then there’s AffyXell, also doing great by all accounts.
Still doesn’t feel great being down here at these levels. I’m pretty fully loaded but have been nibbling.
“The Company is also pleased to announce four B2B contracts to deliver its LiveScores services platform in various territories including Italy, India, Turkey and Africa.”
Spot the odd-one out!
I’m intrigued what they mean by these B2B (business-to-business) contracts… I don’t recall similar in South America, unless they mean a contract with a related telecom company through whom they will provide the service? Or a local company to run the IT infrastructure and regulatory compliance, etc?
Also, “various territories including” - implies more than just these four territories are incoming. If a continent can be regarded as a territory… Lots of avid footballing nations in Africa.
I think an interview to expand on this exciting one liner is in order!
Cheers, I guess I should add bookmakers to the list of revenue sources I suggested.
Assume it’s going to be some football-themed game then…
Partnership with a Turkey-based club may be something to do with basing it a bookmaker-friendly territory? Not that I know anything about Turkey’s online gambling scene vs others. Possibly legacy MOS links to the country? They are mad for football there though, beyond a doubt.
ShearClass - if I’m wrong about Woodford I apologise to anyone I’ve misled there. I have the impression that most of the UK micro- and small-cap biotech sector at the time was beaten down in large part by knock on effects from his fund’s woes, but am not 100% sure of his specific holdings, so should go back and check. I don’t like being wrong, but I appreciate being disavowed of my misconceptions, so thanks.
The rest of my case still stands, and I respectfully disagree about pretty much everything else you said.
Anyone have any insight on what form the esport is likely to be? I’m envisaging some form of FIFA tournament or similar, with money coming primarily from ads and sponsors?
Ppeye - I’m sorry, that’s total nonsense all round.
The co was already beaten down at 20p by Woodford’s forced sale and a weak balance sheet. Since then they have raised >£48m, as well as advancing their own pipelines, adding multiple partners (eg Astrea), and achieving key milestones advancing these partnerships (eg AffyXell and LG Chem).
And for AVA6000, AS/Neil Bell have told us that guidance from regulators is that Phase II could potentially be pivotal, as they are only testing a new delivery mechanism for a pre-existing drug that is already well understood. If they can prove it is safer and at least as efficacious, Phase 3 may be unnecessary.
You’re in luck tonight as I take your first post I can recall seeing as just ill informed rather than cynical. I may be proved wrong yet…
Thanks Wally. Bump.
Not much to add, except it’s fascinating to see how people watch the SP movement, then watch the video and (consciously or not) try to retrofit a negative spin onto what they see to explain the SP movement. With this and the false closing price on Friday, all the psychological tricks are being deployed!
We’re still in the 2022 trading range, despite all the great AVA6000 news.
That said, I was very happy with the content but less so the tone of the interview. It seemed like Paul was trying to give them every opportunity to steer the conversation towards positives, but they were being cautious not to sound too positive. I guess medical ethics dictate what they can say and it is good to see them responding professionally and on top of their brief.
So what is the point of this interview? Shake out the LFT investors and pull in bigger investors from the roadshow? They have no need for funding, so the main thing they need from the stock market right now is defence against a low-ball takeover attempt. For that, they would need to attract sticky investors and shake out flappable investors who would capitulate way too cheap. Meanwhile staving off any offers by not yet showing their hand on how good the data are. Perhaps the communication strategy is perfect if that is the game.
Thanks for the good post regarding margins and revenue, Upside. Steve D really is generating a lot of meaningless negative froth. With exponentially increasing revenues and decent margins, I believe the costs will soon be offset.
Even at the loss rate set out by Steve himself (were it to stay constant rather than reduce), the cash runway would be well over a year. But everything is starting to kick into gear now. Monthly revenues have grown from c.$47k in July (Streams) to c.$120k (Streams, Mexico, Argentina, month 1 Brazil) in Jan - around 6 months. How can anyone say that this car is not shifting up through the gears already, with lots to spare?!
Existing revenue streams have been growing (based on available data). New contracts and revenue streams keep coming online (India & IGS are both yet to hit the reported bottom line). It takes an initial investment outlay to set all of these up, followed by generally lower ongoing costs to keep them running, so profit can really only be judged once they are up and running post-setup.
And so many deals are being set up right now that IMV it’s likely only a matter of weeks to months until the growing profits from everything that is up and running smoothly start to dwarf the capex outlay for whatever the latest new project is. And the balance sheet is plenty healthy.
Nice parallel to draw. I think the delivery platform via Telco is analogous here, but expect very different content.
The relationship with Quanta gives us the LiveScores content for the South American market.
Sounds like the IGS partnership (see 13 Jan RNS) will provide content for the India market. It would be very nice to have a better idea on what exactly that content is, but sounds like it’ll be launching by end Q1, so we should know more by then.
Great news today! It looks like this dovetails neatly with the IGS contract, as MOS will probably look to them for the bulk of the content to deliver through these Indian telco relationships.
It would be interesting to get a peak at some of that content and see what is being sold, but you need to be in a specific country to access http://www.mobilegaming.com/
Anyone got access or know a way to view it?
True… I think I’m often guilty of not being as cautious as my monicker suggests! I am mindful though that SP rarely seems to reflect fair value in AIM, or necessarily respond to news exactly as we anticipate. So I reckon trying to understand the concerns other market participants have that can hold it back are useful. And I’m pretty confident MOS will clear the main ones within two to three months:
- Stop losing money and become cash-flow positive, as they smash through breakeven (depending on levels of capital reinvestment, although it’s software so should be scalable with low friction)
- Clear outstanding 0.5p warrants (although not that much of an issue IMO given the last big RNS on 11th Jan resulted in daily trading volume equivalent to about 1/3 of the outstanding warrants, and they expire soon anyway).
Funny this should be a priority for the oldest POTUS ever! Regardless, it’s a worthy push. Hopefully they support the best therapies already in development, rather than trying to reinvent the wheel.
Experience with SNG in the Activ trials suggests (so far) that the US government is (at least sometimes) willing to support small and non-US based players if they have the best solutions.
I think the IND approval, and our newly appointed influential and well-connected US-based medical advisers, should put us in good stead if there is some opportunity here.
Even though it was only a reduced dose vs standard doxorubicin, there was a chance it could have a worse safety profile, if as well as targeting the tumour it focused delivery on unintended targets elsewhere in the body where FAP-a naturally occurs, meaning some non-tumour tissues or organs get a greater concentration than usual of the chemo warhead. This didn’t seem to be a problem in mice, with their improved survival rates on pro-Dox, and the dose escalation suggests it is not a problem in humans. At least, it doesn’t cause any side effects that are as bad or worse than the ones it solves.
The point is, it was not inevitable that the side effects would be no worse than standard Dox, even given the reduced absolute concentration delivered. Hence, great news to escalate. No unforeseen show-stoppers.
Just needs a modicum of patience. The business is doing great. The SP will ultimately reflect that.
I think well before the end of March, the news flow is likely to show ridiculous value at these levels. We may rerate, warrants or no. I think if one or two big buyers jump in, we may see a rush.
And once the warrants expire, if the company can have shown itself to be profitable by then, well… There would be no more warrants to clear, no need for a raise in the foreseeable future, and with rapidly growing revenue and profit, no roadblocks between 0.4p and the moon. Where we’re going, we don’t need roads!
Fair point. So folk are making plenty money already off ‘skins’ and virtual items in the Fortnite metaverse? It shows that if people are happy to spend time inhabiting a virtual space, many will pay real money for virtual things that are extremely cheap to produce, but I assume provide some form of prestige or individuality in that space. Seems bonkers to me, but then even in the real world I’m the sort of person that’s happy driving my old car until it gets uneconomic to run!
It’s going to be a huge beast, that seems for sure. But to me $2-12 trillion seems like an overly confident uncertainty range on its value, with a very high floor. All the ways I’ve heard of to monetise “the” metaverse (and btw which metaverse? One or many? and who’s in control of it/them?) sound a bit nebulous and unclear.
Tbh, I think it’s going to be one of those trendy things to say your company’s into, but on which very few players ultimately make a lot of money. MOS does seem ahead of the curve with jumping on the metaverse bandwagon in the small and micro cap space, and they have an innovative and strategic BOD. So there could be a big play here. However I’m much more excited about the tangibles in the portfolio until they put some meat on the bones, and ME explains it all in plain English for those of us over the age of 20!
Some say that’s often a good sign and a good time to accumulate - when the tide is out on the clamour of online voices and the price is good.
Lots of holders patiently waiting for:
- Monthly revenue update (chance of $200k+, with the new contract?)
- New territory announcement(s)
- New contract announcements (anytime)
Hope you are all well and have a great week.